New obesity medications are changing treatment, but cost, insurance, specialist access and culturally appropriate care may determine who benefits.
For years, obesity treatment often came down to the same advice: eat less, exercise more and try to lose weight.
That approach is being transformed by a new generation of medications. Drugs such as semaglutide and tirzepatide have given doctors powerful new tools to treat obesity, with some patients losing substantial amounts of weight and seeing improvements in conditions linked to obesity.
But as these treatments become more widely available, another question is emerging: Who is actually getting access to them?
The question is particularly important for Latino Americans, who have some of the highest rates of obesity in the country.
The latest Centers for Disease Control and Prevention data show that Hispanic adults had an obesity prevalence of at least 35 percent in 33 states, the District of Columbia, or U.S. territories with sufficient data. Among non-Hispanic White adults, that threshold was reached in 17 states. The figures are based on self-reported height and weight.
Earlier nationally representative CDC data found that about 46 percent of Hispanic adults had obesity, compared with about 42 percent of U.S. adults overall.
The high prevalence makes access to effective treatment an important public health question. But the answer is not as simple as saying Latino patients are being denied the newest medications.
Treatment patterns vary by health system, insurance coverage and other factors, and research is still developing. What is clearer is that several barriers can stand between having obesity and receiving treatment.
Cost is one. Insurance coverage is another. Access to doctors who specialize in obesity medicine can also be limited, particularly for patients who already face obstacles navigating the health care system.
For some Latino patients, language and communication can add another layer.
A recent study examining Hispanic and Latino adults eligible for metabolic and bariatric surgery found that participants described fear, skepticism, and misinformation about the procedure. Some viewed surgery as a last resort, while others said they relied on family and friends rather than health professionals for information about treatment. The researchers identified the need for culturally tailored, bilingual education and better communication between patients and providers.
That does not mean cultural attitudes explain every treatment disparity. Obesity care is affected by many factors, including income, insurance, access to specialists, physician referrals and the availability of treatment.
And the treatment landscape itself is changing rapidly.
GLP 1 medications have attracted enormous attention, but they can be expensive when insurance does not cover them. Patients also have to remain on treatment to maintain its benefits, making affordability and long term access just as important as getting the initial prescription.
Bariatric surgery presents a different set of challenges. Although it remains one of the most effective treatments for severe obesity, it is still underused among Hispanic and Latino adults, according to recent research.
The stakes are significant because obesity is not simply a question of appearance or weight.
The CDC considers obesity a chronic disease associated with serious health conditions, including heart disease, stroke, and type 2 diabetes. The agency also stresses that obesity is influenced by factors that go well beyond individual choices, including genetics, medications, sleep, stress, access to affordable food, opportunities for physical activity and access to health care.
For Latino communities, that makes the emergence of new obesity treatments both an opportunity and a potential source of another health disparity.
If effective medications and other treatments are available but are less accessible to people who carry a high burden of obesity, the medical breakthrough may not benefit everyone equally.
But there is an important distinction.
The question is not simply whether Latino Americans are receiving GLP 1 medications at lower rates than other groups. Researchers are finding a more complicated picture, with treatment patterns differing depending on the health system and the type of treatment being studied.
The more important question may be whether Latino patients can get appropriate treatment when they need it, afford it and stay with it long enough to benefit.
That includes patients who may never reach an obesity specialist, patients whose insurance does not cover the medication their doctor recommends and patients who are offered treatment but do not have enough information to feel comfortable pursuing it.
It also raises a question about how doctors and patients talk about obesity.
For decades, obesity was often presented primarily as a matter of willpower. The arrival of medications that can directly affect the biological mechanisms involved in weight regulation is changing that conversation.
But a medical breakthrough does not automatically produce equal access.
Latino Americans already carry a disproportionately high burden of obesity. The next challenge may be making sure they are not disproportionately left out of the treatments now changing the way the disease is managed.
The United States has entered a new era of obesity treatment.
The question for Latino communities is whether they will be able to fully participate in it.
